

# Celebration

celebrating life together



## A NOTE FROM MD

Dear Valued Clients,

### **Ensuring Stem Cell Security and Advancing Healthcare: CryoCord's Pledge**

As 2023 comes to a close, I hope everyone is well and healthy. Wishing you all a Merry Christmas!

We are disheartened to learn of the financial challenges faced by Cellsafe International, a situation reminiscent of a Swiss bank's predicament. In light of these developments, we wish to reaffirm our unwavering commitment to the public, with a special focus on our esteemed CryoCord clients. Please rest assured that your invaluable stem cells are securely cryopreserved at Bio-X Centre in Cyberjaya.

CryoCord, established in 2002, has blossomed into a leading and comprehensive medical biotechnology company within the region. Boasting a substantial 65% market share\*, CryoCord's evolution spans from its initial roots in cord blood storage to becoming a fully-fledged cell-based company. Our journey has been marked by consistent growth, expanding into areas such as MSCs, NK cells, CAR T-cell therapy, and other cell-based groundbreaking research.

Operating from our fully-owned 120,000 sq. ft. building, Bio-X Centre, nestled in the smart city of Cyberjaya, Malaysia, we proudly highlight that this accomplishment was achieved without any reliance on bank borrowings. Our state-of-the-art laboratory has garnered a multitude of prestigious local and international accreditations and certifications, including cGMP, AABB, ISO 15189, and more.

*"Your facility was one of the best that I had ever assessed."*

Masi Basiri, BSc, MT  
Lead Quality Assessor, Department of Accreditation & Quality, AABB  
2nd Nov 2021

We take great pride in being a 100% Malaysian company, founded by a group of enthusiasts including a renowned Emeritus Professor in haematology. Our founders and management team have remained unchanged since our inception, driven by an unwavering passion for advancing cell and gene therapy.

Furthermore, we want to emphasize the steadfast financial strength of our company. We have not only outperformed our closest competitor in terms of revenue and profit, but also demonstrated our commitment to advancing healthcare by funding 4 clinical trials approved by local governing bodies.

Your trust and well-being remain our utmost priorities. We express our heartfelt gratitude for your continued support over the years. Thank you for choosing CryoCord.

Sincerely,

*James*

James Then  
MD of CryoCord Group

\*Source: 2019 Frost & Sullivan Malaysia – Asia Pacific Best Practices Awards



[www.cryocord.com.my](http://www.cryocord.com.my) | [info@cryocord.com.my](mailto:info@cryocord.com.my) | 1800 88 3300

This message was sent by [info@cryocord.com.my](mailto:info@cryocord.com.my)

[Unsubscribe](#)